Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up 13.5% during mid-day trading on Thursday . The stock traded as high as $3.58 and last traded at $3.53, with a volume of 1,250,394 shares. The stock had previously closed at $3.11.

Several equities research analysts have issued reports on the company. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Tuesday, May 31st. Maxim Group restated a “buy” rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a report on Wednesday, May 11th. Finally, FBR & Co reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Wednesday, June 22nd.

The company has a 50-day moving average of $5.60 and a 200 day moving average of $4.87. The stock’s market capitalization is $120.70 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.10. Equities research analysts expect that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.